Intra-Articular Injection of an Extended-Release Formulation of Triamcinolone Acetonide Provided Significant Improvement in Pain, Stiffness and Function in Patients with Knee Osteoarthritis

Andrew I. Spitzer, MD, Jay Lieberman, MD, Deryk Jones, MD, David Jevsevar, MD, Joelle Lufkin, MPH, James R. Johnson, Ph.D., Mittie K. Doyle, MD, Neil C. Bodick, MD, PhD

Introduction: FX006, an extended-release formulation of triamcinolone acetonide (TCA), prolongs TCA joint residency and reduces systemic exposure following intra-articular injection in patients with knee osteoarthritis. This multinational phase 3 study (NCT02357459) evaluated effects on pain relief, physical function, stiffness, and quality of life (QoL). Clinical relevance of treatment effects were evaluated post-hoc with application of Minimum Clinically Important Improvement (MCII) criteria from the 2013 AAOS Treatment of Osteoarthritis of the Knee Evidence-Based Guideline.

Methods: Patients with Kellgren-Lawrence grade 2/3 knee osteoarthritis and baseline average daily pain (ADP) score ≥5 to ≤9 on an 11-point numeric rating scale were randomized to FX006 40 mg, placebo, or standard TCA 40 mg. Weekly mean ADP, Western Ontario and McMaster Universities Arthritis Index (WOMAC) A (pain), B (stiffness), and C (function), and Knee Injury and Osteoarthritis Outcome Score (KOOS) QoL were assessed at 4-week intervals over 24 weeks. Safety assessments included adverse event (AE) monitoring and clinical, laboratory, and radiographic evaluations.

Results: 484 patients were treated (FX006, n=161; placebo, n=162; TCA, n=161). Baseline characteristics were similar across groups. FX006 demonstrated statistically significant improvement over placebo in Week-12 mean ADP (P<0.0001); improvement over placebo and TCA in WOMAC A, B, and C, at Weeks 4, 8, and 12 (P<0.05); and improvement over placebo and TCA in KOOS QoL at Weeks 4, 8, and 12 (P<0.05). Improvement produced by FX006 exceeded AAOS thresholds for MCII treatment effect for each WOMAC subscale. Further, FX006, but not TCA, achieved AAOS definition for clinically significant improvement. No serious drug-related AEs occurred. AEs were balanced across arms and generally mild.

Conclusions: In this phase 3 study of patients with knee osteoarthritis, intra-articular injection of FX006 demonstrated clinical significance according to AAOS MCII criteria for improvement in osteoarthritis-specific measures of pain, stiffness, and function with an AE profile similar to placebo.

1 The FDA has not cleared the pharmaceuticals and/or medical devices listed here: FX006 is an investigational pharmaceutical product.